Literature DB >> 12498333

Self-administration of cocaine, alfentanil, and nalbuphine under progressive-ratio schedules: consumer demand and labor supply analyses of relative reinforcing effectiveness.

James K Rowlett1, Joshua S Rodefer, Roger D Spealman.   

Abstract

Progressive-ratio (PR) schedules of intravenous (i.v.) drug self-administration are useful for establishing the relationships between reinforcing effectiveness and pharmacological actions of abused drugs. The authors compared the reinforcing effects of the high-efficacy opioid alfentanil, the low-efficacy opioid nalbuphine, and cocaine using a PR schedule of i.v. drug injection in rhesus monkeys in which the response requirement increased during the experimental session and the initial response requirement (IRR) was varied. Analyses based on either consumer demand or labor supply models of behavioral economics revealed that the relative reinforcing effectiveness of cocaine and alfentanil was greater than that of nalbuphine. These results suggest that PR schedules with varying IRRs can provide meaningful estimates of the relative reinforcing effectiveness of abused drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498333     DOI: 10.1037//1064-1297.10.4.367

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  9 in total

1.  Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

2.  GABAA Receptor Subtypes and the Reinforcing Effects of Benzodiazepines in Remifentanil-Experienced Rhesus Monkeys.

Authors:  Lais F Berro; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2020-05-25       Impact factor: 4.492

3.  Identification and management of nonsystematic purchase task data: Toward best practice.

Authors:  Jeffrey S Stein; Mikhail N Koffarnus; Sarah E Snider; Amanda J Quisenberry; Warren K Bickel
Journal:  Exp Clin Psychopharmacol       Date:  2015-07-06       Impact factor: 3.157

4.  Self-administration of bretazenil under progressive-ratio schedules: behavioral economic analysis of the role intrinsic efficacy plays in the reinforcing effects of benzodiazepines.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2010-08-30       Impact factor: 4.492

5.  Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates.

Authors:  James K Rowlett; Donna M Platt; Snjezana Lelas; John R Atack; Gerard R Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

Review 6.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

7.  Cocaine self-administration on a hold-down schedule of reinforcement in rats.

Authors:  Drake Morgan; Yu Liu; Erik B Oleson; David C S Roberts
Journal:  Psychopharmacology (Berl)       Date:  2008-09-17       Impact factor: 4.530

8.  Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus monkeys: comparison with heroin and antagonism by naltrexone and naloxonazine.

Authors:  Cindy Achat-Mendes; Glenn R Valdez; Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-02-19       Impact factor: 4.530

9.  Reinforcing effects of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys.

Authors:  Nina M Shinday; Eileen K Sawyer; Bradford D Fischer; Donna M Platt; Stephanie C Licata; John R Atack; Gerard R Dawson; David S Reynolds; James K Rowlett
Journal:  Neuropsychopharmacology       Date:  2012-12-27       Impact factor: 7.853

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.